Gastric and Gastroesophageal Junction Adenocarcinoma – 5EU Drug Forecast and Market Analysis to 2024

Date: 2016-08

Gastric and Gastroesophageal Junction Adenocarcinoma – 5EU Drug Forecast and Market Analysis to 2024


Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

GlobalData expects that the cost consciousness of the 5EU healthcare systems, as well as the difficulties in getting reimbursement approval in individual 5EU countries, will limit the growth of the G/GEJAC market. For example, the high price of Cyramza in the US relative to Herceptin received criticism from interviewed EU KOLs. GlobalData expects that, if Eli Lilly imposes the same pricing strategy for Cyramza in the 5EU, it will have difficulty obtaining reimbursement approval. This kind of reimbursement requirement will slow down the growth of the 5EU G/GEJAC market.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


– Overview of G/GEJAC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in 5EU from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting 5EU G/GEJAC market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for G/GEJAC.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in 5EU

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample